Plaque Psoriasis

UCB has resubmitted its biologics license application to the FDA for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis, according to a company press release.

Guselkumab performed comparably in a real-world study of patients with moderate to severe plaque psoriasis as it had in previous clinical trials, according to study findings.

Deucravacitinib demonstrated superiority compared with placebo and apremilast in the treatment of adults with moderate to severe plaque psoriasis, according to findings from a phase 3 trial.

Although psoriasis therapies continue to expand and improve, patients with skin of color still face barriers in access to care and diagnosis, especially if physicians are not adequately trained to identify the condition in all skin types.

The FDA has approved Zoryve cream for the treatment of plaque psoriasis, Arcutis announced in a press release.

Deucravacitinib was associated with improved efficacy and safety compared with both placebo and apremilast in a phase 3 cohort of adults with moderate to severe plaque psoriasis, according to a study.

Results of a long-term efficacy study showed that treatment with Vtama for plaque psoriasis provided improvement beyond 12 weeks with nearly half of patients achieving full clearance.

AVT04, a biosimilar candidate to ustekinumab developed by Alvotech, met the primary endpoint in a confirmatory clinical study of patients with chronic plaque-type psoriasis, according to a company press.

The FDA issued a complete response letter stating a biologics license application for bimekizumab cannot be approved until pre-approval inspection observations are resolved, according to a UCB press release.

A phase 2 trial found the oral tyrosine kinase 2 inhibitor PF-06826647 to be safe and efficacious in the treatment of moderate to severe plaque psoriasis.